XCancer

Study Title

68Ga-FAPI-Biotin PET/CT in Patients With Various Types of Cancer

Study Details

Description:

As a new dual targeting PET radiotracer, 68Ga-FAPI-Biotin is promising as an excellent imaging agent applicable to various cancers. In this study, we observed the safety, biodistribution and radiation dosimetry of 68Ga-FAPI-Biotin in patients with various types of cancer and compared them with the results of 68Ga-FAPI or 18F-FDG imaging to evaluate the dosimetric characteristics and diagnostic efficacy of 68Ga-FAPI.

Sponsor:

First Affiliated Hospital of Fujian Medical University

Contacts:

Weibing Miao, MD

miaoweibing@126.com +86-0591-87981618

Rong Lin, MD

linrong1214@foxmail.com +86-0591-87981619
Government Study Link:

NCT06740240 - Click to see study on ClinicalTrials.gov

Drug Details

18F-FDG

Isotope(s):
Target(s):
  • Glucose Transport

68Ga-FAPI

Isotope(s):
Target(s):
  • FAP

68Ga-FAPI-Biotin

Isotope(s):
Target(s):
  • Biotin
  • FAP

Inclusion

Inclusion Criteria Not Yet Provided

Exclusion

Exclusion Criteria Not Yet Provided

XCancer

© 2021 XCancer Software LLC

Contact XCancer: 402-991-8468